🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

CRC PD Session Lisa Salvatore presenting the results of AVANA study by GONO Foundation: avelumab plus cape-chemoradiation induced 23% pCR in LARC. Happy to have contributed to this study :)

Lisa Salvatore

Great job Lisa Salvatore!

✳️In clinical practice, Reinduction of an Anti-EGFR-based First-line Regimen after off-treatment progression may be chosen. However, few data support this reasonable practice. ✌🏼Now out in The Oncologist our propensity score based analysis of Valentino Study academic.oup.com/oncolo/advance…

Al via il corso di alfabetizzazione per l'oncologo! Seguici per una giornata di discussione sul tumore del pancreas! Per oncologi... E non solo! 🤩

CRC educational session at #Aiom22… no gender balance! Well done ⁦AIOM⁩ ⁦Sara Lonardi⁩ ⁦Lisa Salvatore⁩

Huge compliments 🏅 Lisa Salvatore for receiving Fondazione AIRC per la ricerca sul cancro support for her research project on #rectalcancer. Big researcher, mummy, and friend!

A great pleasure to speak about #Immunotherapy in #larc at the #gemcad IX Symposium in Valencia. Thanks Jaume Capdevila for this great opportunity

🔥Hot of the press: Pembrolizumab in combination with GemCis compared with GemCis in biliary tract cancer The Lancet 👇doi.org/10.1016/S0140-… 🔎KEYNOTE-966🗺️phs-III 1069 pts 💪Significant OS ⬆️ ✅ICI = integral part of systemic 💊 in BTC ESMO - Eur. Oncology ENS-CCA EASL Education #livertwitter

4th may: First day of our meeting in a wonderful location, inspiring talks by @elena_elez Jenny Seligmann and after dinner party. Science is also about friendship and networking!

🔥 AtezoTRIBE: OS data for FOLFOXIRI + Bev vs FOLFOXIRI + AtezoBev in 1st line #mCRC #ASCO23 🔎RAS mut 71%/74%, BRAF mut 14%/8, TMBhigh 10%/12%, high IS IC 32%/32% 👉mPFS 11.5 vs 13.1 mo 👉mPFS2: 19.9 vs 22.6 mo 👉mOS 27.2 vs 33 mo ✅ Benefit for IS IC-high and/or TMB high pMMR

CRC oral session on the updated and OS results of the AtezoTRIBE study by GONO. Again confirmation that Immunoscore IC is able to select patients with immunesensitive pMMR/MSS mCRC and PFS/OS benefit from the addition of atezo to FOLFOXIRI/bev. carlottanto Chiara Cremolini

Lisa Salvatore (Lisa Salvatore) su AIOM Tv per parlare di tumori gastrointestinali. Le evidenze dall’ASCO23: youtu.be/ptv1z-WS8Vo #aiomtv #oncologia #intervista

We are culminating our 🇮🇹National Event with a roundtable session engaging experts and policymakers to reflect upon the key themes we tackled today. #PazienteAlCentro #DigestiveCancers #DigestiveHealth

Gemelli Rome Oncology Team at #ESMO23 in Madrid #ESMO #Gemelli

Filippo Pietrantonio presenting at #ESMO23 CodeBreaK 300 phase 3 study of sotorasib plus panitumumab versus standard care in patients with chemorefractory KRAS-mutated #CRC Chiara Cremolini Lisa Salvatore ESMO - Eur. Oncology NEJM

Filippo Pietrantonio Chiara Cremolini Lisa Salvatore ESMO - Eur. Oncology #ESMO23

Comparison of first-line chemotherapy regimens in unresectable locally advanced or metastatic pancreatic cancer: a systematic review and Bayesian network meta-analysis. Thanks to all my team. Good job guys! ⁦The Lancet⁩ ⁦Università Cattolica⁩ thelancet.com/journals/lanon…

Comparison of first-line CT regimens in unresectable locally advanced or metastatic #pancsm : a systematic review and Bayesian network meta-analysis ⁦The Lancet Oncology⁩ super comprehensive work, congrats ⁦Lisa Salvatore⁩ ‼️ thelancet.com/journals/lanon…

Across the sotorasib/panitumumab and investigator’s choice arms, the distribution of genes showing emergent alterations was comparable, with a mean of 5 genes harboring emergent mutations in each patient (P = .99). #gicsm #ASCO25 | ASCO Lisa Salvatore cancernetwork.com/view/genomic-a…